Innovative Technology 1Globe Health Institute harnesses proprietary advances such as asymmetrical gene-silencing technology (aiRNA), novel nanotechnology, and synthetic biology, positioning itself at the forefront of biotechnology innovation valuable to companies seeking cutting-edge research tools or partnerships.

Growing Revenue Base With annual revenue ranging from 10 to 25 million dollars, 1Globe presents a steady revenue stream and potential for further growth, making it an attractive target for collaborations or investments aimed at expanding biotech solutions.

Research Focus A dedicated research organization with an entrepreneurial and academic hybrid culture, 1Globe specializes in developing novel therapeutics for hard-to-treat diseases, offering opportunities for strategic partnerships in drug development and clinical research.

Industry Alignment Situated within a competitive landscape of universities and public health institutions, 1Globe's focus on fundamental biotech innovation complements larger research entities, providing avenues for collaborative innovation and technology transfer.

Size and Agility As a small team of 11-50 employees, 1Globe offers a nimble and entrepreneurial partner capable of rapid development cycles and personalized collaboration efforts in high-impact biotech projects.